PubMed HealthSearch

Biomedical subjects

M Nobuhara

Publications and source records attributed to M Nobuhara.

At least 19 recordsLinked to original sources

Stable expression of human tissue-type plasminogen activator regulated by beta-actin promoter in three human cell lines: HeLa, WI-38 VA13 and KMS-5.

A high-level and stable expression system of human tissue-type plasminogen activator (t-PA) was accomplished in human cells by selecting a promoter and a host cell line. First, we have constructed two types of t-PA expression plasmids containing 3 kb of the human beta-actin promoter region or 0.3 kb of SV40 early promoter region and these plasmids were transfected into HeLa cells, respectively, and the resulting transfectants were found to secrete various amounts of t-PA derived from the plasmids to the culture media. Southern blot analysis revealed that the beta-actin promoter was more efficient than the SV40 early promoter with regard to the expression level per single copy of the t-PA gene in the transfected HeLa cells. Next, the t-PA expression plasmid containing the beta-actin promoter was also transfected into WI-38 VA13 cells, a human fibroblastic cell line, and KMS-5 cells, a human lymphoid cell line, in order to compare the expression ability of the promoter among these three cell lines. Some of the transfectants from both cell lines were also found to produce t-PA. It was also found that the expression levels in HeLa and WI-38 VA13 seemed to be more efficient than that in KMS-5.

Actins

In vivo antitumor mechanism of natural human tumor necrosis factor involving a T cell-mediated immunological route.

We have investigated the in vivo antitumor mechanism of natural human tumor necrosis factor (n-TNF) isolated from a culture of human leukemic B cell line (BALL-1), especially its action as an immunomodulator, and found that the in vivo antitumor effect of n-TNF on Meth A sarcoma implanted in BALB/c mice pretreated with monoclonal antibody against T cell-specific surface antigen (Thy-1) was significantly diminished. Furthermore, when BALB/c mice were treated with T cell subset-specific monoclonal antibodies, anti-L3T4 or anti-Lyt-2.2, the antitumor effect of n-TNF on Meth A sarcoma was significantly reduced. Therefore, it was suggested that the in vivo antitumor mechanism of n-TNF might involve a T cell-mediated immunological route.

Animals

Expression and excretion of human pancreatic secretory trypsin inhibitor in lipoprotein-deletion mutant of Escherichia coli.

We constructed a gene coding for the 56-amino acid human pancreatic secretory trypsin inhibitor (PSTI), and ligated it on a plasmid downstream from the trp promoter and the signal peptide sequence of alkaline phosphatase. The resulting plasmid was transfected into a lipoprotein deletion mutant (Escherichia coli JE5505) and the plasmid-carrying cells were induced with 3-indoleacrylic acid. A considerable amount (50 micrograms/ml culture) of the mature PSTI protein was detected in the culture supernatant. The excreted PSTI was identical to the natural PSTI protein with respect to the trypsin-inhibiting activity, the N-terminal and the C-terminal amino acid sequences and the amino acid composition.

Base Sequence

Hypomethylation and expression of pepsinogen A genes in the fundic mucosa of human stomach.

We have examined the correlation between the extents of methylation and expression of pepsinogen A genes in normal human tissues. Expression of pepsinogen A mRNA was detected only in the fundic mucosa of the stomach and both CCGG and GCGC sites in the genes region were less methylated in the fundic mucosa than in other non-expressing tissues. Thus, there was an inverse correlation between the extents of methylation and expression of pepsinogen A genes and the role of DNA methylation in the regulation of pepsinogen A genes expression during normal differentiation was suggested.

DNA

The inhibition of neoplastic cell proliferation with human natural tumor necrosis factor.

Purified human natural tumor necrosis factor (n-TNF) was prepared by stimulating human leukemic B cell line (BALL-1) with Sendai virus. The colony formations of all of 18 human cancer-derived abnormal cell lines were suppressed by 10(1)-10(6) U/ml of n-TNF, while n-TNF was nontoxic to all human normal fibroblast cells. This in vitro inhibition of cell growth was reversible. In breast adenocarcinoma MCF7 cells treated with n-TNF a specific decrease of DNA synthesis was observed, and DNA histograms showed a block at G1 in the cell cycle. In vivo studies revealed that n-TNF suppressed the tumor growth of murine Meth A sarcoma, human renal adenocarcinoma (ACHN), malignant melanoma (SK-MEL-28) and glioblastoma (U-373 MG). Isobologram analysis showed that n-TNF synergistically inhibited cell growth in combination with human natural interferon (IFN)-a. In vivo synergism of n-TNF and IFN-a was also found in the U-373 MG tumor model implanted into nude mice.

Animals

Binding of 131I-labeled tissue-type plasminogen activator on de-endothelialized lesions in rabbits.

Tissue-type plasminogen activator (t-PA) which has a high affinity for fibrin in the clot, was labeled with 131I by the iodogen method, and its binding to de-endothelialized lesions in the rabbit was measured to assess the detectability of thrombi. The de-endothelialized lesion was induced in the abdominal aorta with a Fogarty 4F balloon catheter. Two hours after the de-endothelialization, 131I-labeled t-PA (125 +/- 46 microCi) was injected intravenously. The initial half-life of the agent in blood (n = 12) was 2.9 +/- 0.4 min. The degree of binding of 131I-labeled t-PA to the de-endothelialized lesion was evaluated at 15 min (n = 6) or at 30 min (n = 6) after injection of the agent. In spite of the retention of the biochemical properties of 131I-labeled t-PA and the presence of fibrin deposition at the de-endothelialized lesion, the binding of t-PA to the lesion was not sufficiently strong. Lesion-to-control ratios (cpm/g/cpm/g) were 1.65 +/- 0.40 (at 15 min) and 1.39 +/- 1.31 (at 30 min), and lesion-to-blood ratios were 1.39 +/- 0.32 (at 15 min) and 1.36 +/- 0.23 (at 30 min). These results suggest that radiolabeled t-PA may be inappropriate as a radiopharmaceutical for the scintigraphic detection of a pre-existing thrombotic lesion.

Animals

Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction.

Single-chain, urokinase-type plasminogen activator (pro-urokinase), isolated from the conditioned medium of a human renal adenocarcinoma cell line, was administered to six patients with evolving myocardial infarction of less than 5 hours' duration and angiographically confirmed total occlusion of the infarct-related coronary artery. The agent was infused intravenously at a rate of 40 mg over 60 minutes immediately followed in three patients by intracoronary infusion of 20 mg over 30 minutes. In four of the six patients complete reperfusion was obtained during intravenous administration and in one patient after 20 minutes of intracoronary infusion. One patient did not respond. The infusion caused significant changes in the fibrinogen level and generation of fibrinogen breakdown products in only one patient. Single-chain, urokinase-type plasminogen activator can induce clot-selective coronary thrombolysis in patients with acute myocardial infarction.

Aged

[Basic study on human interferon-beta: Part III. The mechanisms of its antitumor effect].

The mechanisms of the direct and indirect antitumor effects of human interferon-beta (IFN-beta, MR-21) were examined. IFN-beta suppressed DNA, RNA and protein synthesis in cells derived from human tumor. The expression of cellular oncogenes (c-Ha-ras and c-myc) in tumor-originated cells was also suppressed by IFN-beta. These results suggest that such suppression is one possible mechanism of the direct anticellular effect induced by IFN-beta. IFN-beta augmented NK cell activity and the ADCC activity of human peripheral blood lymphocytes. It is also suggested that these are two of the immune system-mediated mechanisms responsible for the indirect antitumor effect of IFN-beta in vivo.

Antibody-Dependent Cell Cytotoxicity

The expression of human tumor necrosis factor in E. coli.

cDNA of human natural TNF (n-TNF) obtained by stimulating human leukemic B cell line (Ball-1) with Sendai virus was cloned. Valine-started-TNF (V-TNF) gene was constructed from the cDNA and expressed in E.coli HB101 under the control of a trp promoter by the induction of 3-indoleacrylic acid. The expression level of V-TNF clone was about 10% of the total E.coli protein. On the other hand, the expression level of glutamine started-TNF (Q-TNF) gene having the same SD-ATG sequence which was constructed from V-TNF gene was as low as about 1/20 of that of V-TNF. The nucleotide sequence around ATG (-4 approximately +12) of Q-TNF gene was randomly changed without modifying the coded amino acid sequence, resulting to obtain high expression clones as similar TNF protein yield as that of V-TNF. These clones possessed A residue rich sequence around the initiation codon ATG. These results show that some correlation might exist between the high expression rate and A residue rich sequence around the initiation codon.

Amino Acid Sequence

[Basic study on human interferon-beta: Part I. Antiviral effect].

A study was performed on the antiviral effects of human interferon-beta (IFN-beta, MR-21) produced by a normal human diploid fibroblast cell strain. Of 4 DNA and 9 RNA viruses used in this study, all were inhibited by the IFN-beta and the IC90S obtained were approximately 10(1)-10(3) IU/ml. Results showed that IFN-beta had a very wide antiviral spectrum. The IFN-beta was able to induce 2',5'-oligo A synthetase activity in RSa, HeLa S3 and M08 cell lines but not in HEC-1C cell line lacking receptors for IFN-beta. This strongly suggests that one of the antiviral mechanisms might function through the induction of 2',5'-oligo A synthetase activity through the IFN-beta receptor.

2',5'-Oligoadenylate Synthetase

[Basic study on human interferon-beta: Part II. Anticellular effect].

The anticellular effect of human interferon-beta (IFN-beta, MR-21) was examined in vitro. IFN-beta had a wide anticellular spectrum in proliferation inhibition assay. Of 67 human cell lines including 62 tumor-originated cell lines, 51 were sensitive to IFN-beta (IC50 less than 1,000 IU/ml) while 16 including normal diploid cells were resistant (IC50 greater than or equal to 1,000 IU/ml). These anticellular effects were reversible and there was no relationship between the origins of tumor cell lines and their sensitivity to IFN-beta. IFN-beta induced not only proliferation inhibition but also cytotoxicity in several cell lines. It was suggested that the mode of anticellular effects of IFN-beta was mainly time-dependent.

Cell Count

[Basic study on interferon-beta: Part IV. Antitumor effect on nude mouse-transplanted human tumors].

The effects of human interferon-beta (IFN-beta, MR-21) on the growth of xenografted human tumors in nude mice were examined. IFN-beta was administered to mice with malignant melanoma (SK-MEL-28 and Sk-14) intratumorally at a dose of 1 X 10(5)-3 X 10(5) IU/mouse, with acute leukemia (CCRF-HSB-2) intratumorally at a dose of 3 X 10(5) IU/mouse, with glioblastoma (U-373 MG) intravenously or intratumorally at a dose of 1 X 10(5)-6 X 10(5) IU/mouse, or with uterine cervical tumor (HeLa S3) intravenously at a dose of 0.3 X 10(5)-1 X 10(5) IU/mouse. IFN-beta inhibited the growth of all of these tumors in a dose-dependent manner.

Acute Disease

[Study on human lymphoblastoid interferon-alpha (MOR-22): Part III. Antitumor effect on nude mouse-transplanted human tumors].

The effects of human lymphoblastoid interferon-alpha (MOR-22) on the growth of xenografted human tumors in nude mice were examined. IFN-alpha was administered subcutaneously to mice with renal tumor (ACHN), intratumorally for glioblastoma (U-373MG) or intravenously with uterine cervical tumor (HeLa S3). The dosages of IFN-alpha were 2 X 10(4)-5 X 10(5) IU/mouse for ACHN tumor, 1 X 10(5)-5 X 10(5) IU/mouse for U-373MG tumor and 3 X 10(4)-1 X 10(5) IU/mouse for HeLa S3 tumor. IFN-alpha inhibited the growth of these tumors in a dose-dependent manner.

Animals

[Basic study on human lymphoblastoid interferon-alpha (MOR-22): Part I. Antiviral effect].

A study was performed on the antiviral effects of human interferon-alpha (MOR-22) produced by a human lymphoblastoid cell line (BALL-1). Of 4 DNA and 9 RNA viruses used in this study, all were inhibited by the IFN-alpha and the IC90s obtained were 10(1)-10(4) IU/ml. Results showed that IFN-alpha had a very wide antiviral spectrum. The IFN-alpha was able to induce 2',5'-oligo A synthetase activity in RSa, HeLa S3 and M08 cell lines but not in a HEC-IC cell line lacking receptors for IFN-alpha. This strongly suggests that one of the antiviral mechanisms might function through the induction of 2',5'-oligo A synthetase activity through the IFN-alpha receptor.

2',5'-Oligoadenylate Synthetase

[Study on human lymphoblastoid interferon-alpha (MOR-22): Part II. Anticellular effects].

The direct and indirect anti-cell proliferation effects of IFN-alpha produced by BALL-1 cells were examined. Of 23 cell lines, 7 including 2 normal diploids were resistant to a dose 1000 IU/ml of IFN-alpha. On the other hand, 16 cell lines were sensitive and showed IC50 values of less than 1000 IU/ml. This anti-cell proliferation spectrum showed no specificity to tumor origin and its activity was reversible. Cellular oncogene expression was markedly suppressed by IFN-alpha treatment. This finding showed that there might be some correlation between anti-cell proliferation activity and anti-oncogene expression activity. Furthermore, by activating natural killer cell activity and antibody dependent cell-mediated cytotoxicity, IFN-alpha potentiated indirect anti-cell activity.

Antibody-Dependent Cell Cytotoxicity

Molecular cloning and nucleotide sequence of the HU-1 gene of Escherichia coli.

The Escherichia coli HU-1 was cloned by use of mixed synthetic oligonucleotides (17-mer) predicted from a portion of its amino acid sequence. The amino acid sequence of the HU-1 protein deduced from the nucleotide sequence is in good agreement with the published sequence. The nucleotide sequence has a possible promoter and a typical ribosomal binding site upstream from the translational initiation codon (GUG) of the HU-1 gene.

Amino Acid Sequence

Coronary thrombolysis in dogs with intravenously administered human pro-urokinase.

Coronary thrombolysis was induced by infusion of highly purified human pro-urokinase isolated from a transformed kidney cell line (ACHN) or by infusion of urokinase of urinary origin in anesthetized dogs with 1-hr-old clots in the left anterior descending coronary artery. The clots were induced with a copper coil and thrombolysis was detected by repeat coronary angiography. Intravenous infusion of pro-urokinase at a rate of 10 micrograms/kg/min for 30 min in two dogs did not induce thrombolysis, which was only obtained after 8 and 15 min of its subsequent intracoronary administration. Intravenous infusion of pro-urokinase at a rate of 20 micrograms/kg/min for 30 min in four dogs induced coronary thrombolysis within 23 +/- 2 min (mean +/- SEM). This was not associated with systemic fibrinolytic activation because the alpha 2-antiplasmin and fibrinogen levels did not decrease. Intravenous infusion of urokinase at a rate of 10 micrograms/kg/min for 30 min elicited thrombolysis in four of seven dogs within an average of 19 +/- 2 min. In the other three dogs thrombolysis was only obtained within 11 +/- 3 min of its subsequent intracoronary infusion. Administration of urokinase was associated with systemic fibrinolytic activation as evidenced by a decrease of alpha 2-antiplasmin to about 10% and of fibrinogen to 43 +/- 13% of the preinfusion value. It is concluded that intravenous infusion of pro-urokinase at a sufficiently high rate produces coronary thrombolysis without systemic fibrinolysis in dogs.

Animals